Free Trial

Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

Praxis Precision Medicines logo
$189.99 +27.28 (+16.77%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$187.82 -2.17 (-1.14%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Praxis Precision Medicines Stock (NASDAQ:PRAX)

Advanced

Key Stats

Today's Range
$178.14
$203.58
50-Day Range
$37.71
$189.99
52-Week Range
$26.70
$205.89
Volume
4.42 million shs
Average Volume
1.27 million shs
Market Capitalization
$4.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.27
Consensus Rating
Moderate Buy

Company Overview

Praxis Precision Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

PRAX MarketRank™: 

Praxis Precision Medicines scored higher than 37% of companies evaluated by MarketBeat, and ranked 721st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Praxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    Praxis Precision Medicines has a consensus price target of $218.27, representing about 14.9% upside from its current price of $189.99.

  • Amount of Analyst Coverage

    Praxis Precision Medicines has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Praxis Precision Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($10.22) to ($12.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Praxis Precision Medicines is -15.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Praxis Precision Medicines is -15.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Praxis Precision Medicines has a P/B Ratio of 7.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Praxis Precision Medicines' valuation and earnings.
  • Percentage of Shares Shorted

    13.33% of the float of Praxis Precision Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Praxis Precision Medicines has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Praxis Precision Medicines has recently increased by 10.92%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Praxis Precision Medicines does not currently pay a dividend.

  • Dividend Growth

    Praxis Precision Medicines does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.33% of the float of Praxis Precision Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Praxis Precision Medicines has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Praxis Precision Medicines has recently increased by 10.92%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Praxis Precision Medicines has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 38 news articles for Praxis Precision Medicines this week, compared to 6 articles on an average week.
  • Search Interest

    24 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 243% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Praxis Precision Medicines is held by insiders.

  • Percentage Held by Institutions

    67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Praxis Precision Medicines' insider trading history.
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRAX Stock News Headlines

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $250.00
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $232.00
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Praxis Precision (PRAX) Triples on Stellar Drug Trial Results
See More Headlines

PRAX Stock Analysis - Frequently Asked Questions

Praxis Precision Medicines' stock was trading at $76.96 at the beginning of the year. Since then, PRAX shares have increased by 146.9% and is now trading at $189.99.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its earnings results on Monday, August, 4th. The company reported ($3.31) EPS for the quarter, beating analysts' consensus estimates of ($3.40) by $0.09.
Read the conference call transcript
.

Praxis Precision Medicines's stock reverse split before market open on Wednesday, November 29th 2023.The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

Praxis Precision Medicines' top institutional shareholders include Assenagon Asset Management S.A. (1.95%) and Congress Asset Management Co. (0.14%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola, Dean J Mitchell, Marcio Souza and Jill Desimone.
View institutional ownership trends
.

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/04/2025
Today
10/19/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PRAX
CIK
1689548
Fax
N/A
Employees
110
Year Founded
2015

Price Target and Rating

High Price Target
$360.00
Low Price Target
$28.00
Potential Upside/Downside
+14.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($12.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$182.82 million
Net Margins
N/A
Pretax Margin
-3,232.61%
Return on Equity
-60.07%
Return on Assets
-54.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.31
Quick Ratio
6.31

Sales & Book Value

Annual Sales
$7.77 million
Price / Sales
515.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$23.90 per share
Price / Book
7.95

Miscellaneous

Outstanding Shares
21,050,000
Free Float
20,482,000
Market Cap
$4.00 billion
Optionable
Optionable
Beta
2.62

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:PRAX) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners